Evaluation of ambulatory arterial stiffness index in hyperthyroidism

Özlem TURHAN İYİDİR1,*, Mehmet Muhittin YALÇIN1, Alev EROĞLU ALTINOVA1, Emre ARSLAN1, Bahar UNCU2, Ceyla KONCA DEĞERTEKİN1, Füsun BALOŞ TÖRÜNER1
1Department of Endocrinology and Metabolism, Faculty of Medicine, Gazi University, Ankara, Turkey
2Department of Internal Medicine, Faculty of Medicine, Gazi University, Ankara, Turkey
* Correspondence: ozturhan78@hotmail.com

1. Introduction

Thyroid hormones interact with endothelial function, vascular reactivity, renal hemodynamics, and the renin–angiotensin system (1). Thus, thyroid disorders cause certain hemodynamic changes leading to elevated blood pressure (BP) (2). Overt hyperthyroidism, whether endogenous or exogenous in origin, is associated with increased cardiac output, increased resting heart rate, contractility, ejection fraction, and blood volume with decreased systemic vascular resistance (3). Higher heart rate, frequent atrial premature beats, increased prevalence of atrial fibrillation, increased left ventricular mass, and diastolic dysfunction are also reported in subclinical hyperthyroidism. Several studies showed that there is an association between overt and subclinical hyperthyroidism and increased arterial stiffness, as well as impaired vascular elasticity (4,5).

Twenty-four-hour ambulatory blood pressure monitoring (ABPM) is a noninvasive way of reviewing arterial changes associated with cardiovascular risk. Ambulatory arterial stiffness index (AASI) is a parameter based on the relationship between diastolic and systolic blood pressure derived from ABPM recordings and was recently proposed as a relatively easy way to measure arterial stiffness (6). Although there is quite some debate about the use of AASI as a marker for arterial stiffness, recent prospective studies showed that elevated AASI is an independent predictor for cardiovascular mortality and stroke and is a valuable tool for cardiovascular risk stratification (7,8). Short-term blood pressure variability is defined as the standard deviation or coefficient variation from the mean BP in 24-h ABPM recordings (9). Variability may reflect alterations in cardiovascular regulatory mechanisms, which in turn may also affect cardiovascular prognosis (10).

In this study, we aimed to investigate how AASI and BP variability change in patients with overt and subclinical hyperthyroidism.
2. Methods

2.1. Study groups
We enrolled 59 patients with hyperthyroidism and 25 healthy euthyroid controls in the study. None of the participants had a medical history of chronic disease such as hypertension, diabetes mellitus, chronic renal failure, chronic hepatic disease, and cardiovascular diseases. The hyperthyroid group included 36 patients with subclinical hyperthyroidism and 23 patients with overt hyperthyroidism. Overt hyperthyroidism was defined as suppressed TSH with high free fT3 (fT3) and/or free T4 (fT4) levels, which was caused by Graves’ disease in all cases. Subclinical hyperthyroidism was defined as suppressed TSH with normal fT3 and fT4 levels on two occasions in 6 months. Patients with both endogenous and exogenous subclinical hyperthyroidism were included in the study. The etiologies of endogenous subclinical hyperthyroidism were toxic adenoma or toxic multinodular goiter. For exogenous subclinical hyperthyroidism, patients with differentiated thyroid cancer under TSH suppression due to levothyroxine therapy were included. Among the 23 patients with subclinical hyperthyroidism 12 had toxic adenoma or toxic multinodular goiter and 11 had exogenous subclinical hyperthyroidism due to levothyroxine treatment. Median duration of levothyroxine treatment of the patients with differentiated thyroid cancer was 6 (2–8) years and the mean daily dose of levothyroxine was 125 µg/day.

The study protocol was approved by the ethics committee of Gazi University, and the study was carried out in accordance with the principles of the Declaration of Helsinki. All subjects gave their written informed consent before participating in this study.

2.2. Laboratory measurements
Serum TSH, fT3 and fT4 concentrations were measured with chemiluminescent immunoassay on an automatic analyzer (Architect, Abbott Diagnostics, Abbott Park, IL, USA). Normal ranges were as follows: fT3 (1.71–3.71 pg/mL), fT4 (0.76–1.89 ng/dL), and TSH (0.35–4.94 mIU/L).

2.3. Measurement of BP variability and AASI
Office BP was obtained by calculating the mean of two separate measurements with at least a 5-min interval. BP was measured in every patient during the clinic visit by the same nurse using a mercury sphygmomanometer, on the left arm, after 5 min of rest. ABPM recording was performed for 24 h using Spacelabs model 90207 monitors (Issaquah, WA, USA), on a day of standard activity, with an adequate cuff size of the patient’s arm. The records of readings considered to be valid were ≥80% of the total. The monitor was programmed for obtaining blood pressure measurements every 20 min during the waking period and every 30 min during the resting period. Individual correction was made for the waking and sleeping hours as reported by the patient.

Systolic and diastolic BP variability were expressed by the coefficient of variation (CV) of systolic or diastolic measurements, defined by using relative changes (CV = 100 × s.d./mean). AASI is defined as 1 – (diastolic-on-systolic slope), wherein the slope was determined from a DBP vs. SBP plot by a standard regression procedure (6).

Nocturnal dipping (%) was defined as the percentage decrease in nocturnal systolic BP compared with daytime systolic BP. When patients showed nocturnal dipping of less than 10%, they were defined as “nondippers”.

2.4. Statistical analysis
Analyses were performed using SPSS version 15.0 for Windows (SPSS, Chicago, IL, USA) and GraphPad Prism software version 6.0 (GraphPad, San Diego, CA, USA). Continuous data were presented as means ± standard deviation or median [minimum–maximum], as appropriate. Chi-square (categorical variables) and ANOVA/Kruskal–Wallis (continuous variables) tests were used to assess differences between groups. Post hoc comparisons were carried out using the Mann–Whitney U test for nonparametric variables and Tukey’s test for parametric variables. Bonferroni correction was applied for multiple comparisons of nonparametric variables. Pearson correlation analysis was used to test for correlation of normal variables considered to be associated with AASI, whereas Spearman correlation analysis was used for variables not showing a normal distribution. Multiple linear regression analysis was used to determine predictors among risk factors considered to be related to AASI in the entire population. P < 0.05 was considered to be statistically significant.

3. Results
The demographic, biochemical, and anthropometric characteristics of the patients included in the study are given in Table 1. Mean age of all study subjects was 45.2 ± 10.5 years and 61 (72.6%) of the participants were women. Patients with overt hyperthyroidism were younger than patients with subclinical hyperthyroidism and controls (38.5 ± 9.7 vs. 47.8 ± 10.2 and 47.7 ± 9.0 years, respectively; P = 0.001) (Table 1). The groups were similar in terms of sex distribution (P = 0.295) (Table 1).

In patients with overt and subclinical hyperthyroidism TSH levels were lower and fT4 levels were higher compared with the control subjects (P < 0.001 for TSH; P < 0.001 for fT4), (Table 1). Serum fT3 levels were significantly higher in patients with overt hyperthyroidism compared to those with subclinical hyperthyroidism and the controls (P < 0.001) (Table 1).

Heart rate of the patients with overt hyperthyroidism was significantly higher than that of patients with
subclinical hyperthyroidism and the controls (91 ± 12 vs. 76 ± 7 and 73 ± 6/min, respectively; P < 0.001).

Office systolic BP measurements were significantly higher in patients with overt hyperthyroidism than in patients with subclinical hyperthyroidism and the controls (130.3 ± 10.3 vs. 120.3 ± 9.5 and 123.6 ± 10.4 mmHg, respectively; P = 0.002).

Night-time systolic BP (mmHg) 66.4 ± 5.9 66.4 ± 5.8 67.0 ± 9.3 0.838

Nondipper [n, (%)] 18 (78) 24 (75) 18 (72) 0.882

AASI 0.43 ± 0.15 0.38 ± 0.12 0.42 ± 0.13 0.315

fT3 (pg/mL) 14.2 ± 7.64 3.09 ± 0.33 2.94 ± 0.28 <0.001

fT4 (ng/mL) 3.39 (1.57–7.77) 1.38 (0.38–1.70) 1.17 (0.90–1.59) <0.001

TSH (mIU/L) 0.005 (0.005–0.11) 0.11 (0.001–0.34) 1.32 (0.47–3.79) <0.001

‡: Data are given as median (minimum–maximum) or as mean ± SD, Ohyper: overt hyperthyroidism, Shyper: subclinical hyperthyroidism, BP: blood pressure, CV: coefficient of variation, AASI: ambulatory arterial stiffness index, fT4: free T4, fT3: free T3, TSH: thyroid stimulating hormone

a: Ohyper vs. shyper by the appropriate statistical test.
b: Ohyper vs. control by the appropriate statistical test.
c: Shyper vs. control by the appropriate statistical test.

subclinical hyperthyroidism and the controls (91 ± 12 vs. 76 ± 7 and 73 ± 6/min, respectively; P < 0.001).

Office systolic BP measurements were significantly higher in patients with overt hyperthyroidism than in patients with subclinical hyperthyroidism and the controls (130.3 ± 10.3 vs. 120.3 ± 9.5 and 123.6 ± 10.4 mmHg, respectively; P = 0.002). Twenty-four-hour systolic BP measurements in ABPM recordings were significantly higher in patients with overt hyperthyroidism compared with patients with subclinical hyperthyroidism and the controls (125.4 ± 7.7 vs. 117.9 ± 9.0 and 119.0 ± 9.0 mmHg, respectively; P = 0.005).

Night-time systolic BPs in ABPM recordings were significantly higher in patients with overt hyperthyroidism than in patients with subclinical hyperthyroidism (128.0 ± 8.7 vs. 118.5 ± 8 mmHg, P = 0.001). However, there was no significant difference between patients with overt hyperthyroidism and the control group in terms of daytime systolic BPs in ABPM recordings (128.0 ± 8.7 vs. 122.6 ± 9.4 mmHg, P = 0.08).

Variability of diastolic BP, as expressed by 24-h diastolic CV, was significantly higher in patients with overt hyperthyroidism than in patients with subclinical hyperthyroidism (14.8 ± 2.6 vs. 12.8 ± 2.5%, P = 0.023). There were no statistically significant differences among the overt hyperthyroidism, subclinical hyperthyroidism, and control groups in terms of AASI (0.43 ± 0.15, 0.38 ± 0.12, 0.42 ± 0.13, respectively; P = 0.315). After adjustment for age, the groups were still similar for AASI (P = 0.104).

When the whole group was analyzed, there were significant positive correlations between AASI and fT3 (r = 0.246, P = 0.02) and fT4 (r = 0.219, P = 0.04), while TSH was not correlated with AASI (r = 0.023, P = 0.838). After adjusting for confounders, age, 24-h systolic and diastolic BP, variability of systolic and diastolic BP (24-h systolic and diastolic CV), and fT4 were independent predictors of AASI (r² = 0.460, P < 0.001). Table 2 shows the results of multiple regression analysis.
arterial stiffness index, fT4: free T4
BP: blood pressure, CV: coefficient of variation, AASI: ambulatory arterial stiffness index, fT4: free T4

In our study, we also found significant positive correlations between AASI and free thyroid hormones. Our data are consistent with a previous study by Delitala et al., who found a relationship between fT4 and pulse wave velocity but not with TSH (19). These findings, taken together, suggest that excess thyroid hormones may have some unfavorable effects on arterial stiffness in the long term. Future studies with larger patient groups on this topic are needed.

Age is a major determinant of arterial stiffness in large elastic arteries and stiffness increases especially after the age of 55 (20). The patients with overt hyperthyroidism in our study were younger due to Graves’ disease, which peaks in the third to fourth decade of life (21). Although they were younger than subclinical hyperthyroid patients and euthyroid controls, we did not observe any difference in terms of AASI between the groups. However, there was a positive correlation between fT3 and fT4 and AASI in patients with overt hyperthyroidism despite the younger age of these patients.

BP variability, expressed as CV, was an independent predictor of AASI in our study. This result suggests that AASI may not only measure arterial stiffness but may also represent BP variability. Further studies are needed to evaluate the alteration of BP variability and AASI after maintaining euthyroidism.

Our results also showed that BP measurements obtained instantly at the office, by ABPM throughout the 24 h, and BP variability calculated through ABPM are higher in overt hyperthyroidism compared to subclinical hyperthyroidism.

Short-term BP variability is estimated from ABPM recordings by calculating 24 h BP SD or CV (22). Variability of diastolic BP was higher in patients with overt hyperthyroidism than in patients with subclinical hyperthyroidism in our study. The pathophysiological mechanisms of BP variability in hyperthyroidism remain unclear. Increased short-term BP variability in
overt hyperthyroidism might be explained by increased sympathetic nerve activity and decreased systemic vascular resistance.

There are scarce data about 24-h BP recordings in patients with hyperthyroidism. A previous study showed that the average 24-h BP measurements in patients with hyperthyroidism were similar to those in euthyroid subjects (23). Iglesias et al. reported higher systolic BP in patients with overt hyperthyroidism compared with euthyroid controls and systolic BP decreased after normalization of thyroid hormone levels (24). In our study, in accordance with previous studies, overt hyperthyroid patients had higher systolic BP than euthyroid subjects whereas the groups were similar for diastolic BP throughout the 24-h period. We could not find any difference between patients with subclinical hyperthyroidism and control subjects in terms of systolic and diastolic BP. Our result is consistent with a metaanalysis by Cai et al., which indicated that subclinical hyperthyroidism is not associated with increased BP (25). These findings taken together suggest that blood pressure alterations are more noticeable in overt hyperthyroidism.

The major limitations of our study are the relatively small sample size and the heterogeneity of the etiologies of the patients with subclinical hyperthyroidism.

In conclusion, our study showed that while there was a positive relationship between AASI and free thyroid hormones, AASI did not differ between overt and subclinical hyperthyroidism and short-term BP variability was higher in overt hyperthyroidism than in subclinical hyperthyroidism. Further studies are needed to enlighten the possible relation between arterial stiffness and excess thyroid hormones. Larger prospective studies investigating the alteration in BP variability and AASI after maintaining euthyroidism may potentially broaden our understandings about the vascular effects of thyroid hormones.

References


